The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-55
SponsorUniversity of Arkansas, Fayetteville
About this trial
The goal of this clinical trial is to evaluate the effects of Cannabigerol (CBG) on indicators of Attention-Deficit/Hyperactivity Disorder (ADHD) in a sample of participants indicating/reporting symptoms associated with ADHD. The main question it aims to answer is: Does CBG reduce ADHD-related indicators relative to placebo? Participants will administer an acute dose of placebo or 80mg CBG and complete outcome measures at 45 minutes and 75 minutes. Daily surveys to monitor safety will be administered for one week following administration.
Eligibility criteria
Qualifiers
Between 18 and 55-years-old.
BMI between 18 and 35 kg/m2.
Score a 4 or above on the Adult ADHD Self-Report Scale (ASRS-v1.1) Symptom Checklist Part A.
Meet diagnostic criteria for ADHD with a current severity rating of at least mild as defined by the DIAMOND.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Cannabigerol
- Placebo
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov